Clinical Trials
10 trialsNCT04238715 2026-03-02
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Inc.
Phase 2 Completed
NCT02872714 2025-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 2 Completed
NCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT05253807 2025-08-05
FIGHT-210
Incyte Corporation
Phase 2 Completed
NCT02699606 2025-04-27
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01703481 2025-02-03
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
Phase 1 Completed
NCT04045613 2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2 Completed
NCT04125693 2022-04-01
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
Phase 2 Completed
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT03235570 2020-05-29
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Incyte Corporation
Phase 1 Completed